The ARFGAP3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This polyclonal product contains a heterogeneous pool of edited cells with targeted disruption of the ARFGAP3 gene, providing a loss-of-function model without clonal isolation. The gene-edited population enables investigation of ARFGAP3-dependent processes in a physiologically relevant epithelial background, avoiding potential clonal artifacts. This product is intended for biomedical research applications requiring bulk knockout populations, such as pathway dissection, drug screening, or functional genomics studies.
The A-549 cell line was originally established from a lung adenocarcinoma of a 58-year-old male and is widely used as an in vitro model for non-small cell lung cancer (NSCLC). These adherent epithelial cells exhibit typical adenocarcinoma characteristics, including KRAS mutation and EGFR wild-type status, and are commonly employed in studies of tumor cell biology, therapeutic resistance, and metastasis. The A-549 background provides a clinically relevant context for investigating Golgi-mediated trafficking dysregulation in lung adenocarcinoma, as these cells maintain active secretory pathways and express relevant surface receptors.
ARFGAP3 encodes a GTPase-activating protein specific for the small GTPase ARF1, a central regulator of COPI vesicle trafficking. In the GTP-bound state, ARF1 recruits COPI coatomer complexes to Golgi membranes, promoting vesicle formation. ARFGAP3 accelerates GTP hydrolysis, converting ARF1 to its GDP-bound form, which triggers COPI coat disassembly and facilitates retrograde transport from the Golgi to the endoplasmic reticulum. The protein directly interacts with ARF1 and COPI coatomer subunits, and its activity is stimulated by ARF1-GTP. Key pathway components include the KDEL receptor, which retrieves escaped ER-resident proteins, and Golgi resident proteins such as Giantin and GM130. Disruption of ARFGAP3 is predicted to impair COPI-dependent retrograde trafficking, leading to Golgi morphology defects, mislocalization of Golgi enzymes, and altered cell surface receptor expression.
In A-549 lung adenocarcinoma cells, ARFGAP3 knockout provides a unique tool to dissect the role of Golgi-ER transport in cancer cell behavior. Aberrant Golgi function and altered protein glycosylation are hallmarks of multiple cancers, and defects in retrograde trafficking can influence receptor signaling, cell adhesion, and secretion of matrix metalloproteinases. By disrupting ARFGAP3 in this polyclonal population, researchers can examine how impaired COPI disassembly affects surface levels of receptors such as EGFR or integrins, and how this impacts downstream signaling pathways involved in proliferation, migration, and invasion. The polyclonal nature of the knockout pool allows the study of bulk population responses, which may better recapitulate tumor heterogeneity than clonal lines.
These polyclonal ARFGAP3 knockout cells are suited for functional assays including western blotting for ARFGAP3 and COPI subunits, immunofluorescence staining of Golgi markers (Giantin, GM130) to assess organelle architecture, and RT-qPCR for ARF1-responsive genes. Additionally, the cells can be used in phenotypic assays such as wound healing and Transwell invasion to evaluate migration and invasion capacity, as well as flow cytometry to quantify changes in surface receptor expression. The knockout model also supports secretion assays using luciferase reporters to monitor Golgi-to-plasma membrane trafficking. For additional details or customized requests, please contact Ascent Research.
